Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker KRRO
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | Jean Francois Formela Director | KRRO Korro Bio, Inc. | Sale | 6,870 | $14.30 | $98.2K Sale | Form 4 ↗ |
| Nov 12, 2026 | Jean Francois Formela Director | KRRO Korro Bio, Inc. | Sale | 33,175 | $14.30 | $474.4K Sale | Form 4 ↗ |
| Nov 11, 2026 | Jean Francois Formela Director | KRRO Korro Bio, Inc. | Sale | 617 | $15.60 | $9,625 Sale | Form 4 ↗ |
| Nov 11, 2026 | Jean Francois Formela Director | KRRO Korro Bio, Inc. | Sale | 3,944 | $15.00 | $59.2K Sale | Form 4 ↗ |
| Nov 11, 2026 | Jean Francois Formela Director | KRRO Korro Bio, Inc. | Sale | 2,984 | $15.60 | $46.6K Sale | Form 4 ↗ |
| Nov 11, 2026 | Jean Francois Formela Director | KRRO Korro Bio, Inc. | Sale | 19,042 | $15.00 | $285.6K Sale | Form 4 ↗ |
| Oct 26, 2026 | Lynx1 Capital Management LP 10% owner | KRRO Korro Bio, Inc. | Buy | 25,124 | $11.75 | $295.1K Buy | Form 4 ↗ |
| Oct 23, 2026 | Lynx1 Capital Management LP 10% owner | KRRO Korro Bio, Inc. | Buy | 2,510 | $12.11 | $30.4K Buy | Form 4 ↗ |
| Oct 22, 2026 | Lynx1 Capital Management LP 10% owner | KRRO Korro Bio, Inc. | Buy | 40,000 | $11.04 | $441.5K Buy | Form 4 ↗ |
| Oct 22, 2026 | Lynx1 Capital Management LP 10% owner | KRRO Korro Bio, Inc. | Buy | 12,175 | $9.68 | $117.8K Buy | Form 4 ↗ |
| Sep 14, 2026 | Jean Francois Formela Director | KRRO Korro Bio, Inc. | Sale | 6,602 | $14.12 | $93.2K Sale | Form 4 ↗ |
| Sep 14, 2026 | Jean Francois Formela Director | KRRO Korro Bio, Inc. | Sale | 31,888 | $14.12 | $450.3K Sale | Form 4 ↗ |
| Sep 11, 2026 | Oliver Dolan Senior Vice President, Finance | KRRO Korro Bio, Inc. | Sale | 5 | $13.72 | $68.6 Sale | Form 4 ↗ |
| Sep 11, 2026 | Jean Francois Formela Director | KRRO Korro Bio, Inc. | Sale | 1,750 | $13.99 | $24.5K Sale | Form 4 ↗ |
| Sep 11, 2026 | Jean Francois Formela Director | KRRO Korro Bio, Inc. | Sale | 8,450 | $13.99 | $118.2K Sale | Form 4 ↗ |
| Sep 9, 2026 | Oliver Dolan Senior Vice President, Finance | KRRO Korro Bio, Inc. | Sale | 6 | $13.60 | $81.6 Sale | Form 4 ↗ |
| Sep 8, 2026 | Oliver Dolan Senior Vice President, Finance | KRRO Korro Bio, Inc. | Sale | 7,347 | $13.51 | $99.3K Sale | Form 4 ↗ |
| Aug 26, 2026 | Jean Francois Formela Director | KRRO Korro Bio, Inc. | Sale | 51 | $13.96 | $712 Sale | Form 4 ↗ |
| Aug 26, 2026 | Jean Francois Formela Director | KRRO Korro Bio, Inc. | Sale | 249 | $13.96 | $3,476 Sale | Form 4 ↗ |
| Aug 19, 2026 | Jean Francois Formela Director | KRRO Korro Bio, Inc. | Sale | 4,884 | $14.00 | $68.4K Sale | Form 4 ↗ |
| Aug 19, 2026 | Jean Francois Formela Director | KRRO Korro Bio, Inc. | Sale | 23,584 | $14.00 | $330.2K Sale | Form 4 ↗ |
| Aug 11, 2026 | Jean Francois Formela Director | KRRO Korro Bio, Inc. | Sale | 368 | $13.96 | $5,137 Sale | Form 4 ↗ |
| Aug 11, 2026 | Jean Francois Formela Director | KRRO Korro Bio, Inc. | Sale | 1,775 | $13.96 | $24.8K Sale | Form 4 ↗ |
| Aug 10, 2026 | Lynx1 Capital Management LP 10% owner | KRRO Korro Bio, Inc. | Buy | 1,462 | $13.19 | $19.3K Buy | Form 4 ↗ |
| Aug 6, 2026 | Lynx1 Capital Management LP 10% owner | KRRO Korro Bio, Inc. | Buy | 5,222 | $11.40 | $59.5K Buy | Form 4 ↗ |
| Aug 4, 2026 | Ram Aiyar President and CEO, Director | KRRO Korro Bio, Inc. | Sale | 5,802 | $10.84 | $62.9K Sale | Form 4 ↗ |
| Jul 6, 2026 | Jean Francois Formela Director | KRRO Korro Bio, Inc. | Sale | 8,506 | $13.96 | $118.7K Sale | Form 4 ↗ |
| Jul 6, 2026 | Jean Francois Formela Director | KRRO Korro Bio, Inc. | Sale | 817 | $13.96 | $11.4K Sale | Form 4 ↗ |
| Jul 2, 2026 | Jean Francois Formela Director | KRRO Korro Bio, Inc. | Sale | 14,745 | $14.03 | $206.9K Sale | Form 4 ↗ |
| Jul 2, 2026 | Jean Francois Formela Director | KRRO Korro Bio, Inc. | Sale | 85,955 | $14.03 | $1.2M Sale | Form 4 ↗ |
| Jun 24, 2026 | Jean Francois Formela Director | KRRO Korro Bio, Inc. | Sale | 114 | $14.98 | $1,708 Sale | Form 4 ↗ |
| Jun 24, 2026 | Jean Francois Formela Director | KRRO Korro Bio, Inc. | Sale | 6,979 | $14.60 | $101.9K Sale | Form 4 ↗ |
| Jun 24, 2026 | Jean Francois Formela Director | KRRO Korro Bio, Inc. | Sale | 666 | $14.98 | $9,977 Sale | Form 4 ↗ |
| Jun 24, 2026 | Jean Francois Formela Director | KRRO Korro Bio, Inc. | Sale | 40,679 | $14.60 | $593.9K Sale | Form 4 ↗ |
| Jun 23, 2026 | Jean Francois Formela Director | KRRO Korro Bio, Inc. | Sale | 17,426 | $14.25 | $248.3K Sale | Form 4 ↗ |
| Jun 23, 2026 | Jean Francois Formela Director | KRRO Korro Bio, Inc. | Sale | 101,579 | $14.25 | $1.4M Sale | Form 4 ↗ |
| Jun 22, 2026 | Jean Francois Formela Director | KRRO Korro Bio, Inc. | Sale | 580 | $13.95 | $8,091 Sale | Form 4 ↗ |
| Jun 22, 2026 | Jean Francois Formela Director | KRRO Korro Bio, Inc. | Sale | 3,382 | $13.95 | $47.2K Sale | Form 4 ↗ |
| Jun 16, 2026 | Todd Chappell Chief Operating Officer | KRRO Korro Bio, Inc. | Sale | 3,168 | $10.83 | $34.3K Sale | Form 4 ↗ |
| Jun 16, 2026 | Loic A. Vincent Chief Scientific Officer | KRRO Korro Bio, Inc. | Sale | 3,418 | $10.83 | $37.0K Sale | Form 4 ↗ |
| Jun 16, 2026 | Jeffrey Cerio General Counsel | KRRO Korro Bio, Inc. | Sale | 6,609 | $10.83 | $71.6K Sale | Form 4 ↗ |
| Jun 16, 2026 | Oliver Dolan Senior Vice President, Finance | KRRO Korro Bio, Inc. | Sale | 3,383 | $10.83 | $36.6K Sale | Form 4 ↗ |
| May 29, 2026 | Ram Aiyar President and CEO, Director | KRRO Korro Bio, Inc. | Sale | 15,152 | $12.98 | $196.7K Sale | Form 4 ↗ |
| May 28, 2026 | Jean Francois Formela Director | KRRO Korro Bio, Inc. | Sale | 419 | $13.95 | $5,845 Sale | Form 4 ↗ |
| May 28, 2026 | Jean Francois Formela Director | KRRO Korro Bio, Inc. | Sale | 2,441 | $13.95 | $34.1K Sale | Form 4 ↗ |
| Mar 31, 2026 | Weston Nichols 10% owner | KRRO Korro Bio, Inc. | Buy | 520 | $10.60 | $5,512 Buy | Form 4 ↗ |
| Mar 10, 2026 | Rick Yang 10% owner | KRRO Korro Bio, Inc. | Buy | 207,100 | $11.11 | $2.3M Buy | Form 4 ↗ |
| Mar 10, 2026 | Scott D. Sandell 10% owner | KRRO Korro Bio, Inc. | Buy | 207,100 | $11.11 | $2.3M Buy | Form 4 ↗ |
| Mar 10, 2026 | New Enterprise Associates 17, L.P. 10% owner | KRRO Korro Bio, Inc. | Buy | 207,100 | $11.11 | $2.3M Buy | Form 4 ↗ |
| Mar 10, 2026 | Carmen Chang 10% owner | KRRO Korro Bio, Inc. | Buy | 207,100 | $11.11 | $2.3M Buy | Form 4 ↗ |
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 5:54 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances